Commit Biologics Appoints Esteemed R&D Leader Dr. Janine Schuurman to Board
Portfolio - People | Jan 08, 2025 | Bioqube Ventures NV
Commit Biologics announces the appointment of Dr. Janine Schuurman, a veteran in antibody research and development, to its board of directors. With over two decades of experience, Dr. Schuurman has been instrumental in co-inventing several FDA-approved therapeutic antibodies and developing antibody platform technologies like DuoBody and HexaBody at Genmab. Her presence on the board comes as Commit Biologics aims to nominate drug candidates for cancer and autoimmune diseases by 2025, leveraging its Bi-specific Complement Engaging (BiCE) platform. This platform is designed to activate the body's complement system, an aspect of the immune system with significant therapeutic potential. Commit Biologics, supported by investors like Bioqube Ventures, seeks to enhance the effectiveness of conventional monoclonal antibodies. Dr. Schuurman, who holds a PhD in molecular immunology and has significantly contributed to the field over her career, will bring her invaluable expertise to help Commit advance its pipeline of treatments.
Sectors
- Biotechnology
- Pharmaceutical
Geography
- Netherlands – Dr. Janine Schuurman holds a PhD from the University of Amsterdam and contributes expertise to Commit Biologics.
- Denmark – Commit Biologics was spun out of Aarhus University, emphasizing Danish academic contributions.
Industry
- Biotechnology – Commit Biologics operates in the biotechnology sector, developing advanced therapeutic antibody technologies.
- Pharmaceutical – The appointment of Dr. Schuurman and the focus on FDA-approved therapies places Commit Biologics in the pharmaceutical industry subsector.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Commit Biologics | Target Company | Company | Pioneers in activating the complement system to develop treatments for cancer and autoimmune diseases. |
| Bioqube Ventures | Investor | Company | A key investor supporting Commit Biologics' development in antibody therapeutics. |
| Dr. Janine Schuurman | New Board Member | Person | Renowned for her considerable expertise in antibody research, Dr. Schuurman joins Commit Biologics to leverage her scientific and operational experience. |
| Genmab | Former Employer | Company | A biotechnology company where Dr. Schuurman developed notable therapeutic antibodies and platform technologies. |
| Novo Holdings | Investor | Company | An investment company backing Commit Biologics in its innovative therapeutic developments. |
| Korys | Investor | Company | Another significant investor in Commit Biologics's pharmaceutical endeavors. |